Pharma Industry News

Philip Morris International to acquire inhaled drug company Vectura for $1.2bn

Vectura is developing inhaled drug delivery solutions for a number of diseases including COVID-19

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]